Assessment of biodistribution of 131-IPPA in cardiac and non-cardiac tissues in laboratory animals by imaging

The main substrate of myocardial metabolism is fatty acids which constitutes the principal agent for myocardial consumption and provides almost 60-80% of the energy utilized by the heart in the resting state. Evaluation of cardiac metabolism is important for the assessment of some of cardiac disorders such as Ischemic Heart disease (IHD), cardiomyopathy (functional disorders) and Hypertensive cardiac disorders. Today, almost in all of the developed countries, PET is the first step for diagnosis and assessment of cardiac metabolic disorders. It is, however, too expensive to be used in all centers and are not available in all countries. In this regards, 123-IPPA was introduced as a substitute of PET system for evaluation of cardiac function (metabolism) and it is a complementary method for other Para-clinical methods. We decided to have a preliminary study on IPPA and due to the lack of 123-I, we had to use 131-I. The labeling of IPPA by 131-I, purification and sterilization of 131-1PPA done by the Chemistry Group of Cyclotron Ward and the bio-kinetic and imaging of rat, mice (Laboratory Animals) were performed in the Nuclear Medicine Group. After injection of a proper dose of this radiotracer, the imaging was performed in an appropriate time. In our first images, there were intensive accumulation of tracer in animals' thyroid glands, though after the intake of Lugol solution, the thyroid did not appear and we had a number of excellent images of animal heart that was the target organ